Drugs / MANP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05279742 | Nov 2022 → Apr 2027 expected | chronic kidney disease, diastolic heart failure | Horng Chen | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MANP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05279742 ↗ |
| Route | Subcutaneous | “Single subcutaneous injection 5 µg/Kg” NCT05279742 ↗ |